Michael Gibson, MD, MS

Pretreatment with Intragraft Verapamil Prior to Percutaneous Coronary Intervention of Saphenous Vein Graft Lesions: Results of t

08/01/2008

Matthew H. Otten , BA;

Kent Dauterman , MD;

Thomas A. Ports , MD;

Tony M. Chou , MD;

Michael Gibson , MD, MS;

Andrew D. Michaels , MD, MAS;

Mark Appleby , MD;

Intracoronary calcium channel blockers have been administered during percutaneous coronary interventions (PCI) for the management of reduced coronary flow due to microvascular dysfunction.1–3 More recent studies have shown that intracoronary...

Intracoronary calcium channel...

08/01/2008

Journal of Invasive Cardiology

Treatment of Stent-Jailed Side Branch Stenoses with Rotational Atherectomy

08/01/2008

Michael Gibson , MD, MS;

Roger J. Laham , MD;

Robert T. Sperling , MD;

Kalon K.L. Ho , MD, MSc;

David James , MD;

Joseph P. Carrozza Jr., MD;

Percutaneous intervention of coronary ostial stenoses carries a lower procedural success rate and a higher likelihood of acute complication and need for repeat revascularization. Technical challenges related to the treatment of ostial side...

Percutaneous intervention of...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Effects of B-Type Natriuretic Peptide (Nesiritide) on Coronary
Epicardial Arteries, Systemic Vasculature and Microvessels

08/01/2008

Gui Fu Wu , MD, PhD;

Joanna J. Wykrzykowska , MD, PhD;

Jamal S. Rana , MD;

Duane S. Pinto , MD, MPH;

Michael Gibson , MD, MS;

Jian Li , MD;

Frank W. Sellke , MD;

Roger J. Laham , MD;

Nesiritide (Natrecor®, Scios Inc., Fremont, California) is a recombinant form of human B-type (brain) natriuretic peptide (BNP) that has beneficial vasodilatory, diuretic and neurohormonal effects.1 It activates membrane-bound guanylyl...

Nesiritide (Natrecor®, Scios...

08/01/2008

Journal of Invasive Cardiology